Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Key Inclusion Criteria:

* Women between the age of 18 and 78, inclusive;
* Evidence of platinum-sensitive ovarian cancer following the patient's primary treatment(\>= 6 months);
* Received a 2nd line platinum-based chemotherapy regimen (4-6 cycles) without evidence of progression;
* May have measurable or unmeasurable disease;
* Eastern Cooperative Oncology Group (ECOG) 0 or 1;
* Ability to understand and the willingness to sign a written informed consent document.

Key Exclusion Criteria:

* Women who are pregnant or lactating;
* Prior treatment with a topoisomerase inhibitor;
* Patients with unacceptable organ and/or hematologic reserve at screening;
* Urine protein of \> 500 mg/day or active nephropathy;
* Electrocardiogram (ECG) with evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator;
* History of pancreatitis within the last 12 months;
* Patients treated with previous high dose chemotherapy or stem cell transplant within the last 5 years;
* Use of any investigational agents within 4 weeks of study enrollment;
* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, psychiatric illness or other co-morbidity that presents a risk to the patient as determined by the investigator.